Drug Discovery

Evommune, Accutar to discover drug candidates for chronic inflammatory diseases

Evommune has entered into a new strategic partnership with Accutar Biotechnology to discover new small-molecule drug candidates for chronic inflammatory diseases.

Q32 Bio to merge with Homology Medicines

Biotechnology company Q32 Bio has signed an agreement to merge with Homology Medicines, in an all-stock transaction.

Xentria receives ODD from EMA for anti-TNFα monoclonal antibody

Xentria has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for its anti-TNFα monoclonal antibody, XTMAB-16.

OrsoBio raises $60m to advance treatment for obesity and associated disorders

OrsoBio has raised $60m in Series A financing to advance its metabolic portfolio for the treatment of obesity and associated disorders.

Halozyme, Acumen partner for ENHANZE drug delivery technology

Halozyme Therapeutics and Acumen Pharmaceuticals have signed a global collaboration and non-exclusive license agreement for the ENHANZE drug delivery technology in Alzheimer's disease.

Noramco buys Drug Product Business Unit from Cambrex

US-based Noramco has acquired the Cambrex Drug Product Business Unit, which was formerly known as Halo Pharmaceuticals.

Altasciences concludes US laboratory facility expansion

Integrated drug development solution company Altasciences has completed the expansion of its new laboratory facility in Columbia, Missouri in the US.

Basilea, iNtRON sign deal for antibacterial agent

Basilea Pharmaceutica and iNtRON Biotechnology have signed an exclusive evaluation license and option agreement for the potential first-in-class clinical-stage antibacterial agent, tonabacase.

Canada’s PharmaDrug signs agreement to acquire Securedose Synthetics

Canadian company PharmaDrug has signed a definitive agreement to acquire Securedose Synthetics, a privately-held pharmaceutical research and development company.